Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P61769
UPID:
B2MG_HUMAN
Alternative names:
-
Alternative UPACC:
P61769; P01884; Q540F8; Q6IAT8; Q9UCK0; Q9UD48; Q9UDF4
Background:
Beta-2-microglobulin (B2M) plays a pivotal role as a component of the class I major histocompatibility complex (MHC), crucial for the presentation of peptide antigens to the immune system. Its interaction with exogenously applied M.tuberculosis proteins can lead to decreased export to the cell surface, potentially affecting class I antigen presentation.
Therapeutic significance:
B2M is implicated in Immunodeficiency 43, characterized by a marked reduction in serum concentrations of immunoglobulins and albumin, and in Amyloidosis 8, involving extensive visceral amyloid deposits. Understanding the role of Beta-2-microglobulin could open doors to potential therapeutic strategies for these conditions.